Potential genetic influences on the response to asthma treatment.
Genetic factors play a key role in determining the widely heterogeneous response to pharmacological treatment detectable among asthmatics. In particular, polymorphisms of the genes encoding relevant anti-asthma drug targets contribute significantly to such a variability. Therefore, it is very important to characterize asthmatic patient's genotypes and the related phenotypic patterns, in order to predict the individual therapeutic outcome. This pharmacogenetic approach will eventually help clinicians to optimize and personalize anti-asthma treatment, and will also provide useful information with regard to pre- and post-marketing evaluation of both effectiveness and side effects of newly introduced drugs.
Department of Experimental and Clinical Medicine, University Magna Gaecia of Catanzaro, Catanzaro, Italy. pelaia@unicz.it
Girolamo
G
Pelaia
Alessandro
A
Vatrella
Luca
L
Gallelli
Mario
M
Cazzola
Rosario
R
Maselli
Serafino A
SA
Marsico
D018927:Anti-Asthmatic Agents / Q000494:pharmacology; D001249:Asthma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D001993:Bronchodilator Agents / Q000494:pharmacology; D005938:Glucocorticoids / Q000494:pharmacology; D006801:Humans; D015289:Leukotrienes / Q000096:biosynthesis; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D020641:Polymorphism, Single Nucleotide; D043585:Receptor, Muscarinic M2 / Q000235:genetics; D018343:Receptors, Adrenergic, beta-2 / Q000235:genetics; D011965:Receptors, Glucocorticoid / Q000235:genetics; D013806:Theophylline / Q000494:pharmacology
D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D005938:Glucocorticoids; D015289:Leukotrienes; D010726:Phosphodiesterase Inhibitors; D043585:Receptor, Muscarinic M2; D018343:Receptors, Adrenergic, beta-2; D011965:Receptors, Glucocorticoid; D013806:Theophylline